Accessibility Menu
Csl logo

Csl(OTC) CMXHF

Market Cap$57.68BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)+1,459%
5 Year-42%
1 Year-8%
1 Month+33%
$126.79
+5.27%
+6.35Today
Csl last closing stock price
MetricPriceDate
Last closeUSD 120.442026-09-03
Csl stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.37%USD 120.002026-08-27
1 month+33.41%USD 90.282026-08-04
3 month+70.74%USD 70.542026-06-05
Year to date+5.66%USD 113.982025-12-31
1 year-8.41%USD 131.492025-09-03
3 year-26.58%USD 164.042023-08-31
5 year-42.15%USD 208.202021-09-03
Since inception+1,459.34%USD 7.722003-06-25

Csl Financials at a Glance

Market Cap

$57.68BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$31.21B

Net Income (TTM)

$512.32M

EPS (TTM)

-$5.40

P/E Ratio

-22.33

Dividend

$2.92

Beta (Volatility)

0.31 (Low)

Price

$126.79

Volume

774

Open

$126.79

Previous Close

$126.79

Daily Range

$126.79 - $126.79

52-Week Range

$63.84 - $148.36

Estimated Earnings Date

Feb 9, 2027

CMXHF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Csl

CSL Limited is a global biopharmaceutical enterprise engaged in the discovery, development, production, marketing, and distribution of a wide array of medicinal products. The company operates primarily through two divisions: CSL Behring, which focuses on plasma-derived therapies, and Seqirus, which specializes in innovative vaccines.

Products and Services
  • Plasma-derived therapies for serious medical conditions
  • Innovative influenza vaccines and biotherapeutics
  • Research and development in both plasma and non-plasma treatments
Growth Outlook
  • Strong demand for plasma therapies is expected to drive revenue growth
  • Expansion into emerging markets, particularly in Asia, presents significant opportunities
  • Investment in R&D is projected to enhance product offerings and market position
Financial Highlights
  • Recent quarterly revenue of $7.30 billion reflects robust operational performance
  • Trailing twelve months (TTM) revenue reached $30.80 billion, indicating consistent growth
  • Dividend yield of 2.48% demonstrates commitment to returning value to shareholders
CSL Limited has established itself as a leader in the biopharmaceutical industry, with a strong focus on innovation and patient care. The company's diverse product portfolio and commitment to research and development position it well for future growth. Recent financial performance highlights a solid revenue base and a commitment to shareholder returns, making it an attractive option for potential investors interested in the biotechnology sector.
AI Generated • Aug 31, 2026

Industry

Biotechnology

Sector

Health Care

Employees

29,000

CEO

Gordon Naylor, MBA, CPA

Website

www.csl.com.au

Headquarters

Melbourne, VIC 3000, AU

CMXHF Financials

Key Financial Metrics (TTM)

Gross Margin

47.76%

Operating Margin

25.57%

Net Income Margin

-16.06%

Return on Equity

-15.12%

Return on Capital

15.96%

Return on Assets

-7.52%

Earnings Yield

-4.48%

Dividend Yield

2.42%

Payout Ratio

-53.84%

Stock Overview

Market Cap

$57.68BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

478.91M

Volume

774

Avg. Volume

3.88K

Financials (TTM)

Gross Profit

$15.15B

Operating Income

$8.18B

EBITDA

$10.30B

Operating Cash Flow

$7.11B

Capital Expenditure

-$1.29B

Free Cash Flow

$5.82B

Cash & ST Invst.

$1.51B

Total Debt

$10.88B

Csl Performance Analysis

Csl annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30USD 13,174,000,00025.5%
20242024-06-30USD 14,690,000,00011.5%
20252025-06-30USD 15,430,000,0005.0%
20262026-06-30USD 15,698,000,0001.7%
Csl sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3121.7%
Q42025-06-30-11.7%
Q22025-12-3116.3%
Q42026-06-30-13.5%
Csl annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30USD 4.64-3.3%
20242024-06-30USD 5.4517.4%
20252025-06-30USD 6.1713.4%
20262026-06-30USD -5.35N/A
Csl sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31169.9%
Q42025-06-30-48.7%
Q22025-12-31-60.4%
Q42026-06-30-829.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

$7.30B

+8.2%

Gross Profit

$3.24B

-4.0%

Gross Margin

44.39%

N/A

Market Cap

$57.68BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.99M

N/A

Employees

29,000

N/A

Net Income

-$2.93B

-496.0%

EBITDA

$1.92B

+22.1%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

$1.51B

-8.8%

Total Debt

$10.88B

-10.7%

Accounts Receivable

$3.35B

+26.8%

Inventory

$6.62B

+11.0%

Long Term Debt

$9.74B

-13.3%

Short Term Debt

$1.14B

+20.8%

Return on Assets

-7.52%

N/A

Return on Invested Capital

14.23%

N/A

Free Cash Flow

$1.76B

+33.2%

Operating Cash Flow

$2.08B

+22.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HOCPYHOYA Corporation
$156.60-0.45%
SEMHFSiemens Healthineers AG
$45.23-2.93%
IPSEYIpsen S.A.
$49.15+0.00%
UCBJFUCB S.A.
$255.34+2.71%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.15-0.12%
NVDANvidia
$230.36+0.01%
PATHUiPath
$15.19-0.17%
INTCIntel
$95.80+0.05%

Questions About CMXHF

What is the current price of Csl?

Csl is trading at $126.79 per share.

What is the 52-week range for Csl?

Over the past 52 weeks, Csl has traded between $63.84 and $148.36.

How much debt does Csl have?

As of the most recent reporting period, Csl reported total debt of $10.90B.

How much cash does Csl have on hand?

Csl reported $1.51B in cash and cash equivalents in its most recent financial results.

What is Csl’s dividend yield?

Csl currently has a dividend yield of 2.42%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services